Human MAP2K1 Knockdown Cell Line (WB-Validated)



Catalog #: C61295

Aliases

Mitogen-Activated Protein Kinase Kinase 1; MEK1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MAPK/ERK Kinase 1; MAPKK1; PRKMK1; MKK1; ERK Activator Kinase 1; MAP Kinase Kinase 1; EC 2.7.12.2; MAPKK 1; MEK 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); CFC3; MEL

Background

Gene Name: MAP2K1 NCBI Gene Entry: 5604

Storage

Store at liquid nitrogen for 1 year.

Kit Components

- 1. Human MAP2K1 Knockdown Cell Line (Wb-Validated)
- 2. Wild-type cell line

Parental Cell Line

Human cell line supplied by the client

Validation Methods

RT-qPCR, Western blotting (WB)

Shipping


Shipped on Dry Ice.

Instructions For Use

This knockdown cell line should be paired with wild-type cell line for use.

Note: This product is for research use only.


Validation Data



Genotype	Ct Value
Wild-Type	20.07
Knock-Down	22.31
Δ Ct (Ct _{KD} -Ct _{WT})	2.24 g
% mRNA Reduction	↓ 79% %
% mRNA Reduction	↓ 79 % ^ŏ _{70,8}

Figure 1. RT-qPCR analysis. HeLa cells were infected with *MAP2K1*-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using genespecific primers. Δ Ct (Ct_{KD}-Ct_{WT}) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula: $(1-1/2^{\Delta Ct}) \times 100\%$.

RT-qPCR analysis. HeLa cells were infected with MAP2K1-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers. Δ Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula: $(1-1/2\Delta$ Ct) x 100%.



PAGE 3

Human MAP2K1 Knockdown Cell Line (WB-Validated)

Western blotting analysis. MAP2K1 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting. Hsp90 α served as a loading control. The blots were incubated with primary antibodies (Cat#61295, 1:5,000) against MAP2K1 and Hsp90 α , respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody (Cat#201, 1:20,000). Images were developed using FeQTM ECL Substrate Kit (Cat#226).